News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Bayer Schering Pharma Receives SFDA Approval for MS Drug
December 2, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
GEN -- Chinese regulatory authorities approved Bayer Schering Pharma’s interferon beta-1b, Betaferon®, as a treatment for relapsing-remitting multiple sclerosis (MS). Bayer says it plans to launch the drug in the country by mid-2010.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Asia
MORE ON THIS TOPIC
FDA
FDA mulls compounding for peptides previously flagged over safety risks
April 16, 2026
·
1 min read
·
Nick Paul Taylor
diabetes
Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns
April 16, 2026
·
2 min read
·
Gabrielle Masson
Drug Development
Whitepaper: CDMOs at a Crossroads
April 15, 2026
·
1 min read
·
BioSpace Insights
Obesity
Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data
April 15, 2026
·
2 min read
·
Tristan Manalac